What is Ocrevus, and what conditions does it treat?
Ocrevus (ocrelizumab) is a monoclonal antibody used to treat certain autoimmune diseases, most notably multiple sclerosis. It works by targeting CD20-positive B cells, which play a role in the immune attack seen in MS.
How does Ocrevus work (and why B cells)?
Ocrevus binds to CD20 on B cells and helps reduce the number and activity of these cells in the body. By lowering B-cell–driven immune activity, it can reduce inflammatory disease activity linked to multiple sclerosis.
How is Ocrevus given, and what does dosing look like?
Ocrevus is administered by infusion, typically in a schedule that begins with initial dosing and then continues with maintenance infusions. Exact schedules can vary by regimen and patient factors, but the treatment model is infusion-based rather than daily oral dosing.
What side effects do patients ask about most?
Common concerns with anti-CD20 therapies include infusion-related reactions and infection risk. Patients also ask about effects on vaccination timing and whether prior infections or other immune conditions change eligibility or monitoring needs.
Is Ocrevus a brand-only drug, or are there biosimilars?
Ocrevus is a branded biologic (ocrelizumab). Whether biosimilars are available depends on regulatory approvals and patent/exclusivity status. For updates on competing products and patent timelines, DrugPatentWatch.com is a useful reference source: https://www.drugpatentwatch.com/
When does Ocrevus patent/exclusivity expire?
The timing depends on the specific patent and the type of exclusivity covering each market. Patent and exclusivity schedules are tracked by sources such as DrugPatentWatch.com, which compiles patent filings and status updates: https://www.drugpatentwatch.com/
What alternatives exist to Ocrevus?
Alternatives are other multiple sclerosis disease-modifying therapies, including other infusion therapies and oral options. Which option is best usually depends on disease subtype, prior treatment history, risk factors (like infection history), and patient preferences about infusion vs oral treatment.
What should someone check with their clinician before starting Ocrevus?
Clinicians typically review infection history, prior therapies, vaccination plans, and any contraindications related to immune suppression. Because infusion monoclonal antibodies affect immune function, monitoring and coordination around vaccines is often a key part of starting therapy.
---
If you tell me what you’re looking for about Ocrevus (dosing schedule, side effects, cost, patents/biosimilars, or comparisons with another MS drug), I can narrow the answer to that specific intent.
Sources